Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that data related to REL-1017, the company’s lead product candidate, will be presented in six posters at the 2021 Society of Biological Psychiatry (SOBP) Annual Meeting,
April 29, 2021
· 4 min read